H. Lawrence Remmel Net Worth

The estimated Net Worth of H. Lawrence Remmel is at least $4.75 Thousand dollars as of 17 April 2017. Mr. Remmel owns over 2,500 units of Atossa Therapeutics Inc stock worth over $4,752 and over the last 12 years he sold ATOS stock worth over $0. In addition, he makes $0 as Independent Director at Atossa Therapeutics Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Remmel ATOS stock SEC Form 4 insiders trading

H has made over 5 trades of the Atossa Therapeutics Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently he bought 2,500 units of ATOS stock worth $1,575 on 17 April 2017.

The largest trade he's ever made was buying 5,400 units of Atossa Therapeutics Inc stock on 12 June 2015 worth over $7,020. On average, H trades about 1,175 units every 97 days since 2013. As of 17 April 2017 he still owns at least 3,126 units of Atossa Therapeutics Inc stock.

You can see the complete history of Mr. Remmel stock trades at the bottom of the page.

H. Lawrence Remmel biography

H. Lawrence Remmel Esq. serves as Independent Director of the Company. He is currently a partner of the law firm Pryor Cashman LLP, located in New York City, where he chairs the Banking and Finance practice group. Mr. Remmel joined Pryor Cashman in 1988. His practice includes corporate and banking financings, issues relating to the Investment Company Act of 1940, and intellectual property and licensing issues, in particular in the biotechnology and biocosmeceutical areas. Mr. Remmel served on the Board of Advisors of CytoDel, LLC, an early stage bio-pharmaceutical company developing products for bio-defense, neuronal drug delivery, and musculoskeletal and aesthetic medicine. In February 2018, he became a director of CytoDel, Inc., the successor to CytoDel LLC. In March 2019 he became a director of Aufbau Holdings Limited, an Irish limited company, developing therapeutics in ophthalmology and other areas. He was an associate of the law firm Reboul, MacMurray, Hewitt, Maynard & Kristol from 1984 to 1988, and began his legal career at Carter, Ledyard & Milburn, where he was an associate from 1979 to 1984. He was admitted to the New York bar in 1980 and is a member of the New York State Bar Association. He received his J.D. from the Washington & Lee University School of Law in 1979 and his B.A. from Princeton University in 1975. He currently is a doctoral candidate in the Graduate School of Life Sciences of the University of Utrecht, in the Department of Clinical and Translational Oncology, with a thesis project in hyperplasia and early stage breast cancer. Mr. Remmel has been selected to serve on the Company’s Board of Directors because of his substantial experience as a corporate attorney advising biotechnology companies and his familiarity with the fiduciary duties and the regulatory requirements affecting publicly traded companies.

How old is H Remmel?

H Remmel is 68, he's been the Independent Director of Atossa Therapeutics Inc since 2012. There are 3 older and 5 younger executives at Atossa Therapeutics Inc. The oldest executive at Atossa Therapeutics Inc is Stephen Galli, 73, who is the Independent Director.

What's H Remmel's mailing address?

H's mailing address filed with the SEC is C/O ATOSSA THERAPEUTICS, INC.,, 107 SPRING STREET, SEATTLE, WA, 98104.

Insiders trading at Atossa Therapeutics Inc

Over the last 12 years, insiders at Atossa Therapeutics Inc have traded over $114,740 worth of Atossa Therapeutics Inc stock and bought 274,300 units worth $204,285 . The most active insiders traders include Gregory L Weaver, Steven C Quay, and Shu Chih Chen. On average, Atossa Therapeutics Inc executives and independent directors trade stock every 205 days with the average trade being worth of $38,260. The most recent stock trade was executed by Jonathan Finn on 10 April 2024, trading 25,000 units of ATOS stock currently worth $44,250.

What does Atossa Therapeutics Inc do?

atossa therapeutics, inc. develops and markets medical devices, laboratory tests, and therapeutics to address breast health conditions in the united states. the company's lead program is the development of endoxifen, an active metabolite of tamoxifen which is in phase ii studies to treat and prevent breast cancer. it is also developing intraductal microcatheter technology to target the delivery of therapies, including fulvestrant, immunotherapies, and chimeric antigen receptor t-cell therapies, directly to the site of breast cancer. the company was formerly known as atossa genetics inc. and changed its name to atossa therapeutics, inc. in january 2020. atossa therapeutics, inc. was founded in 2009 and is headquartered in seattle, washington.

Complete history of Mr. Remmel stock trades at Atossa Therapeutics Inc

Atossa Therapeutics Inc executives and stock owners

Atossa Therapeutics Inc executives and other stock owners filed with the SEC include:

• Steven Quay,
  Chairman of the Board, President, Chief Executive Officer
• Kyle Guse,
  Chief Financial Officer, General Counsel, Secretary
• Dr. Steven C. Quay,
  Chairman, CEO & Pres
• Kyle Guse CPA, Esq., CPA,
  CFO, Gen. Counsel & Sec.
• Shu-Chih Chen,
  Director
• Gregory Weaver,
  Independent Director
• Scott Gordon,
  IR Contact Officer
• Richard Steinhart,
  Independent Director
• H. Lawrence Remmel,
  Independent Director
• Stephen Galli,
  Independent Director
• Janet Rose Rea MSPH, RAC,
  Sr. VP of Regulatory, Quality & Clinical Affairs
• Delly Behen P.H.R.,
  VP of Admin. & HR
• Heather Rees,
  VP of Fin. & Accounting
• Janet Rose Rea,
  Sr. VP of Regulatory, Quality & Clinical Affairs
• Scott Youmans,
  Chief Operating Officer
• Heather Rees,
  SVP, Finance and Accounting
• Jonathan Finn,
  
• Tessa Cigler,
  
• Christopher S. Destro,
  Sr. VP, Sales and Marketing
• John Barnhart,
  Director
• John E Sawyer,
  See Remarks
• Peter J. Carbonaro,
  Sr. Vice President, Operations
• Ben R Chen,
  Sr. VP of Glob. Reg. Affairs
• Alexander D Cross,
  Director